Clinical Report: Identifying Risk Factors Linked to Aggressive Tumor Characteristics in Papillary Thyroid Microcarcinoma

Overview

This systematic review and meta-analysis identifies key clinical and molecular risk factors associated with aggressive phenotypes in papillary thyroid microcarcinoma (PTMC).

Background

Papillary thyroid microcarcinoma (PTMC) is increasingly diagnosed due to advancements in imaging techniques. While often indolent, certain aggressive phenotypes can lead to significant clinical implications. Understanding the risk factors associated with these aggressive characteristics is crucial for effective risk stratification and management.

Data Highlights

Key Findings

• Male sex is associated with increased odds of central lymph node metastasis (OR = 1.86).
• Younger age (<45 and <55 years) correlates with higher risk for aggressive PTMC (OR = 1.61 and OR = 1.89, respectively).
• Larger tumor size (>5 mm) significantly increases the risk of extrathyroidal extension (OR = 3.00).
• Multifocality and bilaterality are linked to higher odds of lymph node metastasis (OR = 1.96 and OR = 1.70, respectively).
• BRAFV600E mutation is a relevant risk factor for aggressive tumor characteristics (OR = 1.51 for CLNM and OR = 2.19 for ETE).

Clinical Implications

This information can guide individualized treatment strategies and monitoring protocols.

Conclusion

The study highlights significant clinical and molecular risk factors.

Related Resources & Content

1. Frontiers | Risk Factors associated with aggressive tumor phenotypes in Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-Analysis
2. The Journal of Clinical Endocrinology & Metabolism — Validation of the ATA Risk Assessment for Papillary Thyroid Microcarcinoma: Insights from a Real-World Study in Italy
3. The Journal of Clinical Endocrinology & Metabolism — Assessing Risk Factors in Thyroid Cancer: The Complex Role of Pathologists
4. Expert Commentary: The Importance of Lymph Node Ratio and Ki-67 Levels in Papillary Thyroid Carcinoma
5. Factors Influencing Progression During Active Monitoring of Low-Risk Papillary Thyroid Microcarcinoma in Adults: The Role of Thyroid-Stimulating Hormone, Age, and Tumor Size
6. Executive Summary of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
7. 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
8. Long-Term Outcomes of Active Surveillance and Immediate Surgery for Adult Patients with Low-Risk Papillary Thyroid Microcarcinoma: 30-Year Experience - PubMed
9. Frontiers | Risk Factors associated with aggressive tumor phenotypes in Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-Analysis